Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. [electronic resource] by
- Popat, Rakesh
- Plesner, Torben
- Davies, Faith
- Cook, Gordon
- Cook, Mark
- Elliott, Peter
- Jacobson, Eric
- Gumbleton, Todd
- Oakervee, Heather
- Cavenagh, Jamie
Producer: 20130412
In:
British journal of haematology vol. 160
Availability: No items available.
|
|
11.
|
|
|
12.
|
|
|
13.
|
Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy. [electronic resource] by
- Sirohi, Bhawna
- Powles, Ray
- Cavanagh, Jamie
- Oakervee, Heather
- Dyer, P
- Rintala, T
- Kulkarni, Samar
- Rudin, Claudius
- Horton, Clive
- Treleaven, Jennifer
- Morgan, Gareth
Producer: 20070529
In:
Hematology (Amsterdam, Netherlands) vol. 12
Availability: No items available.
|
|
14.
|
|
|
15.
|
|
|
16.
|
Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. [electronic resource] by
- Popat, Rakesh
- Oakervee, Heather E
- Hallam, Simon
- Curry, Nicola
- Odeh, Liz
- Foot, Nicola
- Esseltine, Dixie-Lee
- Drake, Mary
- Morris, Curly
- Cavenagh, Jamie D
Producer: 20080703
In:
British journal of haematology vol. 141
Availability: No items available.
|
|
17.
|
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. [electronic resource] by
- Popat, Rakesh
- Brown, Sarah R
- Flanagan, Louise
- Hall, Andrew
- Gregory, Walter
- Kishore, Bhuvan
- Streetly, Matthew
- Oakervee, Heather
- Yong, Kwee
- Cook, Gordon
- Low, Eric
- Cavenagh, Jamie
Producer: 20180116
In:
The Lancet. Haematology vol. 3
Availability: No items available.
|
|
18.
|
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial). [electronic resource] by
- Popat, Rakesh
- Brown, Sarah R
- Flanagan, Louise
- Hall, Andrew
- Gregory, Walter
- Kishore, Bhuvan
- Streetly, Matthew
- Oakervee, Heather
- Yong, Kwee
- Cook, Gordon
- Low, Eric
- Cavenagh, Jamie
Producer: 20200504
In:
British journal of haematology vol. 185
Availability: No items available.
|
|
19.
|
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. [electronic resource] by
- Oakervee, Heather E
- Popat, Rakesh
- Curry, Nicola
- Smith, Pat
- Morris, Curly
- Drake, Mary
- Agrawal, Samir
- Stec, Jim
- Schenkein, David
- Esseltine, Dixie-Lee
- Cavenagh, Jamie D
Producer: 20050930
In:
British journal of haematology vol. 129
Availability: No items available.
|
|
20.
|
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. [electronic resource] by
- Popat, Rakesh
- Oakervee, Heather
- Williams, Catherine
- Cook, Mark
- Craddock, Charles
- Basu, Supratik
- Singer, Charles
- Harding, Stephen
- Foot, Nicola
- Hallam, Simon
- Odeh, Liz
- Joel, Simon
- Cavenagh, Jamie
Producer: 20090526
In:
British journal of haematology vol. 144
Availability: No items available.
|